

Steve Abrams

Partner

Philadelphia

Biography


As Global Co-Head of our Life Sciences & Health Care industry sector, Steve Abrams works with clients in many areas of the life sciences ecosystem, such as oncology therapies, pain products, dermatology therapies, vaccines, diagnostics, medical devices and drug/device combinations, orphan drugs, and gene therapies. He also counsels a variety of companies that provide services to the life sciences industry.

Steve has successfully negotiated and completed a range of life sciences transactions, with a particular focus on capital market offerings (IPOs, follow-on offerings, ATMs, RDOs, PIPES, and private placements), collaboration/licensing transactions, and M&A transactions. Additionally, he regularly advises public and privately held clients, including boards of directors, on securities, governance, transactional, and a range of other complex issues.

Steve is a member of the board of directors of inTEST Corporation (NASDAQ: INTT), and a member of its Audit and Compensation Committees. He is Chair of its Nominating Committee as well. Steve has lectured in front of various groups and published articles on securities, governance, and M&A issues.

Representative experience

Represented a commercial-stage pharmaceutical company in its US\$46m follow-on offering led by Cowen and Cantor Fitzgerald.



Phone

+1 267 675 4671

Fax

+1 267 675 4601

Email

steve.abrams@hoganlovells.com

Practices

Mergers and Acquisitions

Corporate Governance and Public
Company Representation

Capital Markets

Securities and Public Company
Advisory

Commercial

Industries

Life Sciences and Health Care

Private Capital

Areas of focus

Shareholder Activism

Cross-border Mergers and

Represented a commercial-stage pharmaceutical company in its US\$100m and US\$50m follow-on offerings led by Jefferies, Cowen, and Piper Jaffray.

Represented a commercial-stage pharmaceutical company in its US\$70m follow-on offering and US\$90m at-the-market offering.

Represented a clinical-stage pharmaceutical company in its US\$50m at-the-market offering.

Represented an Australian-based clinical-stage pharmaceutical company in its US\$40m private placement.

Represented a clinical-stage biotechnology company in its US\$40m and US\$30m follow-on offerings and its US\$35m at-the-market offering.

Represented a publicly traded biotechnology company in its US\$63m sale.

Represented a publicly traded commercial-stage pharmaceutical company in an acquisition of a privately held specialty pharmaceutical company.

Represented a pre-clinical-stage pharmaceutical company in its US\$48m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

Represented a clinical-stage pharmaceutical company in its US\$80m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*

Represented a NASDAQ Global Market developer and supplier of injectable drug delivery systems in a US\$45m underwritten offering of common stock.*

Represented a clinical-stage biopharmaceutical company in its US\$40m at-the-market equity program led by Cowen and Company.*

Represented a publicly traded clinical-stage pharmaceutical company in a US\$65.6m underwritten offering of common stock.*

Acquisitions

Hostile Takeovers and Takeover Defense

Public Company Mergers and Acquisitions

Special Committee and Independent Director Representations

Cell, Tissue, and Gene Therapies

Licensing and Commercial Transactions

Education and admissions

Education

J.D., University of Pennsylvania Law School, cum laude, 1995

B.A., Rutgers, The State University of New Jersey, summa cum laude, 1990

Bar admissions and qualifications

Pennsylvania

New Jersey

Accolades

'Steve Abrams ... stand[s] out for [his] expertise representing small to mid-sized public biotech and pharma companies.'

Client quoted in Legal 500 US 2022: Healthcare – Life Sciences

'Steve Abrams ... stand[s] out for [his] outstanding client service,

Represented a provider of integrated clinical documentation solutions for the U.S. health care system in a US\$130m acquisition.*

Represented a provider of integrated promotional outsource services to life sciences companies in its US\$55m acquisition.*

Represented a specialty pharmaceutical company in its US\$138m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented a specialty pharmaceutical company in its acquisition of a commercial-stage specialty pharmaceutical company and related equity and debt financing.

Represented a clinical-stage oncology company in its reverse merger into a NASDAQ-listed public company.

Represented a specialty pharmaceutical company in its co-promotional agreement with a major orthopaedic company.

Represented a commercial-stage specialty pharmaceutical company in its US\$120m follow-on public offering through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented Arbutus Biopharma Corp. on an at-the-market equity offering led by Jefferies.

*Matter handled prior to joining Hogan Lovells.

Awards and rankings

- Corporate/M&A: Securities (Pennsylvania), *Chambers USA*, 2022-2023
- Finance: Capital Markets: Equity Offerings, Recommended, *Legal 500 US*, 2017-2018, 2020-2023
- Healthcare: Life Sciences, Recommended, *Legal 500 US*, 2021-2023
- Corporate and M&A, Notable Practitioner, *IFLR1000*, 2020
- Pharmaceuticals and life sciences, Notable Practitioner, *IFLR1000*, 2020

tremendous level of experience and expertise, and business-savvy legal representation.'

Client quoted in Legal 500 US 2022: Capital Markets – Equity Offerings

Steven Abrams is a highly-regarded securities practitioner who regularly handles cross-border mandates.

Chambers USA 2023

'Steven is exceptionally responsive and helpful.' ... 'One of the most prominent securities lawyers in the market.'

Clients quoted in Chambers USA 2023

- Life Sciences Star, *LMG Life Sciences*, 2018-2019

Latest thinking and events

- Press releases
 - Hogan Lovells represents Optinose in its US\$55 million registered direct offering
- News
 - 2024 Life Sciences & Health Care Horizons
- News
 - Highlights of new SEC rules on climate-related disclosures
- Press releases
 - Hogan Lovells Guides Mind Medicine Inc. on its US\$175m Underwritten Offering of Common Shares and Concurrent Private Placement
- Press releases
 - Hogan Lovells advises Perspective Therapeutics on a series of strategic transactions with Lantheus and a US\$69 million follow-on public offering of equity securities
- News
 - Agencies issue guidance on delayed SEC reporting of material cybersecurity incidents